TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01864785

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fixation Combined With Fusion
Description: Articular process fusion with bone graft was carried out after screw fixation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fixation Alone
Description: Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
Study: NCT02008825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Utilization of ViSiGi calibration tube
Description: Utilization of ViSiGi calibration tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual non suction Bougie
Description: Usual non suction Bougie
Study: NCT02969902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy® device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held computer
Study: NCT03190187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulation
Description: Spinal manipulation based on orthopaedic manual therapy approach

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: Patients will receive simulated spinal manipulation without force application
Study: NCT00135304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensipar®
Description: Cinacalcet hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D administered IV
Study: NCT00805740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active anidulafungin
Description: Subjects in this arm will receive active anidulafungin and placebo caspofungin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Caspofungin
Description: Subjects in this arm will receive active caspofungin and placebo anidulafungin
Study: NCT03881007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash with LCM
Description: Subjects will mouthwash daily with LCM and before/after sex

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash with LCM
Description: Subjects will mouthwash daily with LCM and before/after sex

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash with placebo
Description: Subjects will mouthwash daily with placebo and before/after sex

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash with placebo
Description: Subjects will mouthwash daily with placebo and before/after sex
Study: NCT04954807

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: human milk fortified
Description: HMF will be given 6 scoops a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be given six scoops a day
Study: NCT01072409

Intervention type: DEVICE
Group type: OTHER
Intervention: Nucleus 5 Cochlear implant
Description: Cochlear implant surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: Cochlear implantation
Description: Implantation
Study: NCT04181879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: * GPs allocated to the intervention will be given access to the intervention package and asked to perform medication reviews with approximately 10 patients on two occasions (initial and 6-months follow-up).~* The intervention package consists of two components: (a) an online video demonstrating how GPs can improve appropriate polypharmacy during typical consultations with older patients; (b) a patient recall process (appointment with the GP for a medication review).~* GPs will be asked to schedule appointments with consenting patients (telephone or online consultations where a face-to-face consultation is not possible). During these appointments, GPs will undertake medication reviews ('a structured, critical examination of a person's medicines with the objective of reaching an agreement with the person about treatment, optimising the impact of medicines, minimising the number of medication-related problems and reducing waste').
Study: NCT01047202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza A/H1N1 vaccine
Description: Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza A/H1N1 vaccine
Description: Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Seasonal trivalent vaccine
Description: Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
Study: NCT02983487

Intervention type: PROCEDURE
Intervention: Nasopharyngeal sampling
Description: Nasopharyngeal sample by aspiration or swabbing

Intervention type: PROCEDURE
Intervention: Nasopharyngeal sampling
Description: Nasopharyngeal sample by aspiration or swabbing

Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Blood sample by the tip of a finger (fingerprick)

Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Blood sample by the tip of a finger (fingerprick)
Study: NCT02892266

Intervention type: OTHER
Intervention: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
Study: NCT01495494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nasal Strip
Description: Breathe Right Nasal Strips - Clear small/medium strip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype Nasal Dilator
Description: Prototype Nasal Dilator AB2R11
Study: NCT03201055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Snore PAP System
Description: The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
Study: NCT03569202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piiloset Trehalose Emulsion Eye Drops
Description: Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops 3 times daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Eye Drops
Description: Topical application of preservative-free multidose Hyaluronic Acid Eye Drops 3 times daily
Study: NCT01859377

Intervention type: DRUG
Group type: OTHER
Intervention: V0498 - A mg
Description: Single oromucosal administration

Intervention type: DRUG
Group type: OTHER
Intervention: V0498 - A mg
Description: Single oromucosal administration

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: Single oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: Single oral administration
Study: NCT02932787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Height-adjustable workstation
Study: NCT05773404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Neurodynamics and Passive axial hip mobilisation/distraction
Description: The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active therapy
Description: Active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2.5.3. Combined therapy
Description: The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles and active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves.
Study: NCT03575104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant will be administered as tablets, orally, once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant will be administered as tablets, orally, once daily in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablets, orally, once daily in the evening.
Study: NCT03932994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT on Health
Description: This intervention consists of an online canvas course based on Acceptance and Commitment Therapy, focused on increasing healthy diet and physical activity and addressing barriers to change. The intervention also consists of weekly phone coaching calls.
Study: NCT02665429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual prescribing data profile and self-assessment
Description: Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
Study: NCT01087541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program 6-hour standardized
Description: 6-hour standardized program for adults ( doctors and nurses )
Study: NCT00254410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
Study: NCT03390179

Intervention type: DRUG
Intervention: Steroid Drug
Description: mesure of the glucose concentration

Intervention type: DRUG
Intervention: Steroid Drug
Description: mesure of the glucose concentration
Study: NCT04248205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
Study: NCT05370573

Intervention type: OTHER
Intervention: No intervention
Description: Observational - no interventions
Study: NCT03094000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND
Description: Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .~The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-E
Description: The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
Study: NCT01471665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily for up to 16 days.
Study: NCT01742260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair of cranial defects by tissue engineering
Description: Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
Study: NCT02975830

Intervention type: RADIATION
Intervention: Three dimensional CT based images
Description: Right bronchial angle, left bronchial angle

Intervention type: RADIATION
Intervention: Three dimensional CT based images
Description: Right bronchial angle, left bronchial angle

Intervention type: RADIATION
Intervention: Three dimensional CT based images
Description: Right bronchial angle, left bronchial angle

Intervention type: RADIATION
Intervention: Three dimensional CT based images
Description: Right bronchial angle, left bronchial angle
Study: NCT00584233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Breast MRI
Study: NCT02222714

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC
Description: 3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC
Description: 3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC
Description: 3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC
Description: 3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
Study: NCT00732173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Undergo SUCCEED lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Undergo SUCCEED lifestyle intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo SUCCEED lifestyle intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Undergo SUCCEED lifestyle intervention
Study: NCT03100903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130
Description: single dose
Study: NCT02947243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR distraction via Oculus Rift
Description: In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
Study: NCT01260155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment C: 40 mg new tablet formulation administered with food
Study: NCT00542620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
Study: NCT03644628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair of anterior and apical pelvic organ prolapse
Description: Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic repair of anterior and apical pelvic organ prolapse
Description: Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
Study: NCT01007214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Elective prostatectomy
Study: NCT00929955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin added to TAU Simvastatin 20mg taken as once daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to TAU
Study: NCT00214461

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine diluent buffer (Placebo)
Description: 0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile toxoid vaccine (2 µg)
Description: 0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile toxoid vaccine (10 µg)
Description: 0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile toxoid vaccine (50 µg)
Description: 0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
Study: NCT04628923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QUADRATUS LUMBORUM BLOCK
Description: QUADRATUS LUMBORUM BLOCK BY PARASPINOUS SAGITTAL SHIFT APPROACH
Study: NCT01484782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) automated calls
Description: Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
Study: NCT03118596

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
Study: NCT02947243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: As per unit's protocol
Study: NCT00553280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Study: NCT03118596

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Protector
Description: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
Study: NCT01609595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium 2,2 dimethylbutyrate
Description: Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
Study: NCT02689323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation
Study: NCT01688050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® TX2® Low Profile Endovascular Graft
Description: Treatment of Blunt thoracic aortic injuries (BTAIs)